Growth Metrics

Emergent BioSolutions (EBS) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Emergent BioSolutions (EBS) over the last 16 years, with Q3 2025 value amounting to $149.5 million.

  • Emergent BioSolutions' Receivables - Net rose 2324.81% to $149.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.5 million, marking a year-over-year increase of 2324.81%. This contributed to the annual value of $154.5 million for FY2024, which is 1910.99% down from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Receivables - Net is $149.5 million, which was up 2324.81% from $79.8 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Receivables - Net high stood at $290.1 million for Q2 2023, and its period low was $79.8 million during Q2 2025.
  • For the 5-year period, Emergent BioSolutions' Receivables - Net averaged around $193.5 million, with its median value being $189.2 million (2022).
  • Per our database at Business Quant, Emergent BioSolutions' Receivables - Net surged by 6577.14% in 2023 and then tumbled by 5934.79% in 2025.
  • Emergent BioSolutions' Receivables - Net (Quarter) stood at $278.9 million in 2021, then plummeted by 42.92% to $159.2 million in 2022, then grew by 19.97% to $191.0 million in 2023, then fell by 19.11% to $154.5 million in 2024, then decreased by 3.24% to $149.5 million in 2025.
  • Its Receivables - Net stands at $149.5 million for Q3 2025, versus $79.8 million for Q2 2025 and $203.7 million for Q1 2025.